exhibited relatively low levels of PTS symptom severity, with only 5.6% of the sample meeting criteria for PTSD, limiting the extent to which these findings are generalizable to clinical samples with PTSD. Additionally, PTS symptom severity was found to be related to only coping and expansion motives for marijuana use, at the zero-order level, and neither DT nor PTS symptom severity were found to be related to marijuana use frequency. Though these findings are consistent with prior study of sub-clinical populations (Bonn-Miller et al., 2007; Buckner et al., 2007; Simons & Gaher, 2005; Zvolensky et al., 2009), alternate relations have been observed among clinical populations (e.g., the relation between PTSD symptoms and marijuana use frequency; Bonn-Miller et al., in press; Bremner et al., 1996). It is important for future work to replicate and extend the present study among clinical populations with PTSD and/or greater variability in PTS symptom severity. Finally, substance use disorders, including marijuana use disorders, were not assessed. Though the measure employed to determine current marijuana use status and frequency has been used often in prior literature (e.g., Bonn-Miller et al., 2007; Bonn-Miller & Zvolensky, 2009), future research may benefit from the assessment of drug potency and marijuana
